Cytokinetics said Q4 2025 total revenues rose 5.0% to USD 17.8 million, while net loss widened to USD 183.0 million, or USD 1.50 per share (basic and diluted). R&D expenses increased 11.5% to USD 104.4 million and G&A expenses rose 47.1% to USD 91.7 million in Q4. As of Dec. 31, 2025, the company reported USD 1.22 billion in cash, cash equivalents and investments. For FY 2025, total revenues were USD 88.0 million and net loss was USD 785.0 million, or USD 6.54 per share (basic and diluted). FY 2025 R&D expenses were USD 416.0 million and G&A expenses were USD 284.3 million. On the business side, Cytokinetics highlighted FDA approval of MYQORZO (aficamten) for adults with symptomatic obstructive HCM and said its U.S. launch began in January with first prescriptions dispensed within days of availability; it also reported approvals in China and the EU, and noted an expected first European launch in Germany in Q2 2026. The company said it submitted a supplemental NDA to the FDA for MAPLE-HCM in Q1 2026 and expects to share topline results from ACACIA-HCM in Q2 2026. Cytokinetics guided 2026 GAAP combined R&D and SG&A expense at USD 830 million to USD 870 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241600PRIMZONEFULLFEED9660330) on February 24, 2026, and is solely responsible for the information contained therein.
Comments